In the last three months, 6 analysts have published ratings on Travere Therapeutics TVTX, offering a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 1 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 1 | 0 | 0 |
Analysts have set 12-month price targets for Travere Therapeutics, revealing an average target of $14.83, a high estimate of $19.00, and a low estimate of $9.00. Witnessing a positive shift, the current average has risen by 4.07% from the previous average price target of $14.25.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive Travere Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Edward Nash | Canaccord Genuity | Raises | Buy | $18.00 | $15.00 |
| Ed Arce | HC Wainwright & Co. | Raises | Buy | $19.00 | $17.00 |
| Laura Chico | Wedbush | Maintains | Outperform | $13.00 | - |
| Ed Arce | HC Wainwright & Co. | Maintains | Buy | $17.00 | $17.00 |
| Mohit Bansal | Wells Fargo | Raises | Equal-Weight | $9.00 | $8.00 |
| Laura Chico | Wedbush | Maintains | Outperform | $13.00 | - |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Travere Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Travere Therapeutics compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Travere Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Travere Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Travere Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into Travere Therapeutics's Background
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
A Deep Dive into Travere Therapeutics's Financials
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Travere Therapeutics's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 53.58%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Travere Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -200.12%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Travere Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -37.53%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Travere Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -11.12%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Travere Therapeutics's debt-to-equity ratio surpasses industry norms, standing at 2.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
